APPLICATIONS PUBLISHED 27 NOVEMBER 2002

Published: 1-Jun-2003

The following patent applications are taken from the weekly European Patents Bulletin and give the publication number and date of publication as well as the title of the specification and the applicant. An asterisk denotes that application was made through the International Patent Cooperation Treaty (PCT). Further details on individual patent applications can be obtained from the EPO at Schottenfeldgasse 29, A-1072 Vienna. T +43 1521 260 F +43 1 52126 4492


The following patent applications are taken from the weekly European Patents Bulletin and give the publication number and date of publication as well as the title of the specification and the applicant. An asterisk denotes that application was made through the International Patent Cooperation Treaty (PCT). Further details on individual patent applications can be obtained from the EPO at Schottenfeldgasse 29, A-1072 Vienna. T +43 1521 260 F +43 1 52126 4492

  • Novel use of pulmonary surfactant for the prophylaxis and treatment of chronic pulmonary diseases
    Altana Pharma 1259222*

  • Protein matrix materials, devices and methods of making and using thereof
    Gel-Del Technologies 1259223*

  • Cochleate formulations and their use for delivering biologically relevant molecules
    Biodelivery Services; University of Medicine and Dentistry of New Jersey 1259224*

  • Liposomes
    Lipoxen Technologies 1259225*

  • Anaesthetic formulations
    Maelor Pharmaceuticals 1259226*

  • Method for producing pharmaceutical dosage forms
    Bayer 1259227*

  • Therapeutic compsns for pulmonary delivery
    Elan Drug Delivery 1259228*

  • Use of PDE V inhibitors
    Merck Patent 1259229*

  • Partial fatty acid oxidation inhibitors in the treatment of congestive heart failure
    CV Therapeutics 1259230*

  • Naphthoquinone derivatives as CD45 inhibitors
    AstraZeneca 1259231*

  • Method for identifying an agent for treatment of NIDDM diabetes by interaction with compound UO126
    Biovitrum 1259232*

  • Modulation of bone formation
    The University of Sheffield 1259233*

  • 3-heteroarylidenyl-2-indolinone compounds for modulating protein kinase activity and for use in cancer chemotherapy
    Sugen 1259234*

  • Tyrosine kinase inhibitors
    Merck 1259235*

  • Tyrosine kinase inhibitors
    Merck 1259236*

  • Treatment or prevention of prostate cancer with a COX-2 selective inhibiting drug
    Merck 1259237*

  • Stable and labile benzimidazole pharmaceutical compsns
    Deboek, Arthur; Van der Biest, Francis; Baudier, Phillippe 1259238*

  • Use of COX-2 inhibitors as gastroprokinetics
    Glaxo Group 1259239*

  • Agents, such as nicotinamide or CADPR, for the treatment of skin disorders
    Harel, Avikam; Bloch, Olga 1259240*

  • The use of scopolamine salts
    Fundacafo de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP) 1259241*

  • Use of PDGF receptor tyrosine kinase inhibitors for the treatment of diabetic nephropathy
    Novartis; The University of Melbourne; Southern Health; Atkins, Robert; Chadban, Stephen James; Cooper, Mark Emmanuel; Gilbert, Richard Ernest; Hill, Prudence Ann; Kelly, Darren James; Nikolic-Paterson, David John 1259242*

  • Bupropion metabolites and methods of their synthesis and use
    Sepracor 1259243*

  • Veterinary compsns for the treatment of parasitic diseases
    New Pharma Research Sweden 1259244*

  • Novel compsns and uses of dictyostatin compounds
    Harbor Branch Oceanographic Institution 1259245*

  • Use of DPP-IV inhibitors for the treatment of diabetes
    Novo Nordisk 1259246*

  • DNA encoding human acid-sensing ion channel BNAC4 (ASIC4)
    Ortho-McNeill Pharmaceutical 1259247*

  • Methods for treating, screening for, and detecting cancers expressing vascular endothelial growth factor D
    Ludwig Institute for Cancer Research 1259248*

  • Method of detecting the presence of target bacteria or a target component carbohydrate antigen thereof
    Binax 1259249*

  • Endoparasiticidal agents
    Bayer 1259250*

  • Novel method for down-regulation of amyloid
    Pharmexa 1259251*

  • Soluble tumour necrosis factor receptor and IL-4 inhibitor for the treatment of medical disorders
    Immunex Corp 1259252*

  • Methods for promoting production of myelon by Schwann cells
    ZymoGenetics 1259253*

  • Method of treatment of anorectal disorders
    K King & Co 1259254*

  • PAI-2 conjugates for the treatment and imaging of cancer
    University of Wollongong; Medical Scitec Australia; Biotech Australia 1259255*

  • Antigenic complexes and methods
    Genvec 1259256*

  • In ovo protection against infectious bronchitis
    Wyeth 1259257*

  • Mucosal adjuvant formulation
    Biotec Pharmacon 1259259*

  • Combination therapy for the treatment of inflammatory and respiratory diseases
    Eli Lilly 1259260*

  • Pharmaceutical compsns comprising terbinafine
    Novartis 1259261*

  • Hydrolytically degradable carbamate derivatives of poly(ethylene glycol)
    Shearwater Corp 1259262*

  • Method for treating inflammatory bowel disease and other forms of gastrointesinal inflammation
    The Regents of the University of California; Tel Aviv Sourasky Medical Centre 1259264*

  • Nucleic acid formulations for gene delivery and methods of use
    Valentis 1259265*

  • Aminoadamantane derivatives as therapeutic agents
    Panorama Research 1259477*

  • Covalent derivatives of alkanolamides of monocarboxylic acids functionally active on the CB2 cannabinoid receptor
    Innovet Italia 1259478*

  • Acetoacetylated diamines and polyamines
    Lonza 1259479*

  • Process for the preparation of organic polyisocyanates
    Huntsman International 1259480*

  • Substituted benzyguanidines, method for their production, their use as a medicament or diagnostic agent and a medicament containing the same
    Aventis Pharma 1259481*

  • Sulphur containing compounds
    University Health Network 1259482*

  • Method for producing (b)-alaninamides
    Lonza 1259483*

  • Carboxamindes useful as inhibitors of microsomal triglyceride transfer protein and of apolipoprotein B secretion
    Novartis 1259484*

  • Benzamides and related inhibitors of Factor XA
    Millennium Pharmaceuticals 1259485*

  • Pyridine-amidines as modulators of P38 MAP kinase
    Iconix Pharmaceuticals 1259486*

  • 2-amino-nicotinamide derivatives and their use as VEGF-receptor tyrosine kinase inhibitors
    Novartis 1259487*

  • Ortho-sulphonamido aryl hydroxamic acids, process for their preparation and their use as matrix metalloproteinase inhibitors
    Wyeth 1259488*

  • Aryl fused azapolycyclic compounds
    Pfizer Products 1259489*

  • Synthesis of epothilones, intermediates thereto and analogues thereof
    Sloan Kettering Institute for Cancer Research 1259490*

  • 4-imidazole derivatives of benzyl and restricted benzyl sulphonamides, sulphamides, ureas, carbamates and amides and their use as alpha-1A agonists
    Abbott Laboratories 1259491*

  • Substituted piperazine derivatives as MTP inhibitors
    Boehringer Ingelheim Pharma 1259492*

  • Substituted piperzine compounds
    CV Therapeutics 1259493*

  • Aryloxyacetic acids for diabetes and lipid disorders
    Merck 1259494*

  • Indane derivatives and their use as cell adhesion inhibitors
    Aventis Pharma 1259495*

  • (Hetero)aryl-substituted heterocyclic enaminones, production thereof and use thereof as herbicides, acaricides and insecticides
    Bayer CropScience 1259496*

  • Novel quinoline ligands and metal complexes for diagnosis and therapy
    Mallinckrodt 1259497*

  • 8,8A-dihydro-indeno 1,2-D]thiazole derivatives, substituted in position 8A, a method for their production and their use as medicaments, eg anorectic agents
    Aventis Pharma Deutschland 1259498*

  • Thiazepinyl hydroxamic acid derivatives as matrix metalloproteinase inhibitors
    Fujisawa Pharmaceuticals 1259499*

  • Method for the preparation of citalopram
    H Lundbeck A/S 1259501*

  • Biologically active analogues of discodermolide
    Harbor Branch Oceanographic Institution 1259502*

  • Producing liquid crystals with CF20 bond
    Merck Patent 1259503*

  • Pyrazole ether derivatives as anti-inflammatory/analgesic agents
    Pfizer Products 1259504*

  • Novel 1,3-dihydro-2H-indol-2-one, preparation method and pharmaceutical compsns containing same
    Sanofi-Synthelabo 1259505*

  • Pyrazinone thrombin inhibitors
    Merck 1259506*

  • Pseudopolymorph of (-)-cis-2-(2-chlorophenyl)-5,7-dihydroxy-8 4R-(3S-hydroxy-1-methyl)piperidinyl]-4H-1-benzopyran-4-one
    Aventis Pharmaceuticals 1259507*

  • Novel biarylcarboxamides
    AstraZeneca 1259508*

  • Process for the preparation of 6-methyl-2-(4-methyl-phenyl)-imidazo 1,2A]pyrimidine-3-(N,N-dimethyl-acetamide) and intermediates
    Egis Gyrogyszergyar 1259509*

  • Tricyclic dihydropyrazolone and tricyclic dihydroisoxazolone potassium channel openers
    Abbott Laboratories 1259510*

  • 3,9-diazabicyclo 3.3.1]nonane derivatives with analgesic activity
    Il Centro Consortile Ricerche Neuropsicofarmacologiche 1259511*

  • Pteridine compounds for the treatment of psoriasis
    AstraZeneca 1259512*

  • A novel crystalline form of N-4-2-(2-amino-4,7-dihydro-4-oxo-3H-pyrrolo 2,3-D]pyrimidin-5-yl)ethyl]benzoyl]-L-glutamic acid and process therefore
    Eli Lilly 1259513*

  • 3-(pyrolyllactone)-2-indolinone compounds as kinase inhibitors
    Sugen 1259514*

  • Thienopyridine derivatives and their use as anti-inflammatory agents
    Takeda Chemical Industries 1259515*

  • Purification of an organometallic compound by recrystallisation
    Akzo Nobel 1259516*

  • You may also like